article
Raman: In-Depth Focus 2016
In this Raman In-Depth Focus: Raman as a valuable tool in high-throughput screening; Use of Raman in analysing polymorphism in pharmaceutical drugs; Upcoming Raman calibration standards; Raman roundtable...
List view / Grid view
Bristol-Myers Squibb Company
news
CHMP adopts positive opinion of Opdivo in NSCLC and RCC
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
news
FDA approves expanded use of Daklinza in HCV genotypes 1 and 3
8 February 2016 | By Victoria White
The expanded label for Daklinza includes three additional patient populations: HCV patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV...
news
BMS, Pfizer and Portola team up to bring andexanet alfa to Japan
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
news
CHMP adopts positive opinion of Empliciti in multiple myeloma
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
news
Phase 3 study of Opdivo in head and neck cancer meets primary endpoint
29 January 2016 | By Victoria White
The study demonstrated superior overall survival (OS) in patients receiving Opdivo compared to the control arm...
news
EC approves Daklinza in three new HCV patient populations
29 January 2016 | By Victoria White
The expanded label allows for the use of Daklinza (daclatasvir) in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV...
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
Opdivo + Yervoy regimen receives expanded FDA approval
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
news
NICE says ‘yes’ to Opdivo (nivolumab) in melanoma
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
news
Trial of Adcetris and Opdivo in non-Hodgkin lymophoma starts
23 December 2015 | By Victoria White
The phase 1/2 clinical trial will evaluate Adcetris (brentuximab vedotin) in combination with Opdivo (nivolumab) in patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas...
news
BMS divests its HIV R&D assets to ViiV Healthcare
18 December 2015 | By Victoria White
ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...
news
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
news
Empliciti efficacy benefits demonstrated in extended follow-up data
7 December 2015 | By Victoria White
The follow-up data demonstrated that Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone had an improvement in progression-free survival in patients with relapsed or refractory multiple myeloma...
news
FDA approves Empliciti for the treatment of multiple myeloma
1 December 2015 | By Victoria White
Empliciti (elotuzumab) has been approved as combination therapy with Revlimid (lenalidomide) and dexamethasone (ERd) in patients who have received one to three prior therapies.
